Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California. Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington’s Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis.

RemoteMDx, Inc., together with its subsidiaries, markets and deploys offender management programs, combining patented global positioning system tracking technologies, intervention-based monitoring capabilities, and case management services in the United States. It markets, monitors, and sells the TrackerPAL device, which is used to monitor convicted offenders that are on probation or parole in the criminal justice system. The TrackerPAL device utilizes global positioning system and cellular technologies in conjunction with a monitoring center. The company also sells home security and personal emergency response systems. RemoteMDx, Inc. has strategic relationships with Puracom, Inc.; Inovar, Inc.; and euromicron AG. The company is headquartered in Sandy, Utah.

Response Genetics Inc. company was founded in 1999 and is headquartered in Los Angeles, California. Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suite, which comprises KRAS Mutation and EGFR Amplification tests. The KRAS Mutation test identifies tumors that have low probability of response to EGFR-directed therapy. The EGFR Amplification test assesses the probability of benefit from EGFR-directed therapy. The company also offers ResponseDX: Colon test suite that includes ERCC1, KRAS Mutation, and TS tests. The ERCC1 test is a test for the probability of response to platin-based therapies and the analysis of RRM1 tests for the probability of response to gemcitabine-based therapies. The TS test measures the probability of response to 5-fluorouracil -based chemotherapy. In addition, Response Genetics, Inc. is developing tests of other types of cancer that identify genetic profiles of tumors that recur after surgery. The company has collaboration agreements with Shanghai BioChip Company, Ltd. to provide pharmacogenomic testing services in China using the company's RGI-1 extraction technology; and Hitachi Chemical Co., Ltd. to use its techniques to extract genetic information from formalin-fixed paraffin-embedded tissue samples. It offers its services in the areas of oncology for oncologists, hospitals, and physician offices through the sales force.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Roche s.r.o in the Czech Republic is just a hop, skip, and a jump away from parent company Roche Holding Ltd. in nearby Switzerland. Its operations are focused more on the parent company's diagnostic products than on its traditional pharmaceuticals; Roche s.r.o. has two facilities in Prague for manufacturing and distributing tests for Hepatitis B and C, HIV, cancer, and other diseases. One is devoted exclusively to diabetic products -- diabetes is a growing problem in the Czech Republic. Roche s.r.o. also markets pharmaceuticals made at other Roche facilities, including such popular therapies as cancer drugs Avastin and Herceptin, lymphona drug MabThera, and osteporosis drug Bonviva.

Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of minimally/non-invasive, blood or serum-based molecular diagnostics tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer and chronic infections. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the company's microRNA-based cancer diagnostic tests; and a testing and administrative services agreement with Teva Pharmaceutical Industries Ltd. to distribute these tests in Turkey and Israel.

Rubicon Genomics, Inc. was founded in 2000 and is based in Ann Arbor, Michigan. Rubicon Genomics, Inc. engages in the development and commercialization of pre-analytical and analytical kits and licenses to improve genetic, epigenetic, and expression analysis in research, diagnostic, and other clinical applications. It offers GenomePlex whole genome amplification platform, a research and diagnostic pre-analytical tool to amplify and standardize DNA for genetic analysis; TransPlex whole transcriptome amplification platform, which amplifies and standardizes RNA sequences for expression analysis; and MethylPlex platform, which amplifies and standardizes the methylated portion of DNA for methylation analysis. The company also provides kits for research and diagnostics applications; contract services to biotech, pharma, and diagnostic companies and institutions; OEM reagents for diagnostic manufacturing; partnerships to develop and commercialize cancer biomarkers and tests; out-licenses for cancer biomarkers; and out-licenses for kits and processes. In addition, it offers fee-for-service products, including whole genome amplification services, single-cell whole genome amplification services, whole transcriptome amplification services, and methylated DNA amplification and analysis services. The company serves pharmaceutical, biotechnology, diagnostic, government, academic, and research institutions.

Rules-Based Medicine, Inc. company was founded in 1998 and is headquartered in Austin, Texas. Rules-Based Medicine, Inc., a life sciences company, focuses on the development and commercialization of molecular diagnostic tests based on novel biomarker patterns primarily for the psychiatric market. It develops molecular diagnostic tests using its proprietary multi-analyte profiling, or MAP, technology that helps to screen large sets of well-characterized clinical samples from both diseased and non-diseased populations against a menu of biomarker immunoassays. The company’s pharmaceutical services consist of MAP testing services, custom MAP services, multiplexed immunoassay kits, and TruCulture and other co-culture services. It markets its laboratory testing products and services primarily to drug development professionals at pharmaceutical and biotechnology companies.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Spectral Diagnostics Inc. company was founded in 1991 and is based in Toronto, Canada. Spectral Diagnostics Inc. operates in the in vitro diagnostic testing market. The company focuses on the development, manufacture, and sale of diagnostic tests that provide information to physicians. Its products include EAA Endotoxin Activity Assay, a diagnostic test in the field of sepsis; and RapidWN West Nile Virus IgM Test, an assay that helps physicians in obtaining diagnostic information regarding exposure to the West Nile virus. The company also offers other proprietary biochemicals, including monoclonal antibodies and recombinant proteins. Spectral Diagnostics Inc. has operations primarily in Canada, the United States, and Europe.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.